Oral FDG scan: Evaluating the feasibility, scan quality and ease of administration when FDG is consumed orally rather than administered by IV.
Study summary
Typically, PET scans involve an IV injection of 18F-FDG that helps identify cancer. Patients are scanned 60 minutes after injecting 18F-FDG. This study aims to assess the feasibility of a different method of administration - oral ingestion (rather than IV) of 18F-FDG through delayed imaging to identify the optimal time for scanning after consuming the drug. The study will aim to recruit 15-24 individuals who will receive two PET scans - one using delayed oral 18F-FDG imaging and a second regular 18F-FDG. The analysis will focus on establishing a suitable protocol for this administration route while considering patient preference and image quality.
Eligibility
Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥19 years
* Participants who have received a standard of care \[18F\]FDG PET/CT and are willing to undergo a study specific oral \[18F\]FDG PET/CT within 2 weeks.
Exclusion Criteria:
Participant Inclusion Criteria
* Age ≥19 years
* Participants who have received a standard of care \[18F\]FDG PET/CT and are willing to undergo a study specific oral \[18F\]FDG PET/CT within 2 weeks.
Participant Exclusion Criteria
* Pregnant or breast-feeding
* Medically unstable (e.g., acute illness, unstable vital signs)
* Urinary incontinence/catheter.
* Immobile, frail or vulnerable patients who cannot leave the department and would require an uptake room in any case.
* Patients whose fasting blood sugar at the SOC PET was \>11.0 mmol/l
* Unable to swallow.
* Patients with nasogastric tubes, percutaneous gastrostomy or other non-anatomical routes for nutrition.
* Unable to lie flat for 1h (subset of participants - first 5 participants only).
* Claustrophobia requiring medication.
* Undergoing active treatment or assessment of an upper digestive tract tumor (stomach/esophagus)
* Unable to provide written consent
* Patients receiving biguanide anti-hyperglycemic agents (e.g. Metformin).
* Insulin dependent diabetics.
Primary outcome measure(s)
Number of hours for radiopharmaceutical to be cleared from stomach for optimal imaging — Periprocedural To identify an acceptable imaging time to achieve gastric clearance of the radiopharmaceutical (time post administration in hours)
Image quality compared to the standard of care FDG scan — within 2 weeks of the scan They shall be asked to rate the quality of each scan on a five point Likert scale (5 being the highest, 1 being the lowest).
To assess participant preference for this method of administering radiopharmaceutical — periprocedural Participants will be given a sheet with 4 questions to answer about their experiences with the new mode of administration. The questions are:
1. Which scan did you prefer: oral or the injection? Why?
2. Where do you prefer to wait: in the uptake room or outside the department? Why?
3. What did you do during the waiting time for the study scan? (select all that apply) Walk / read/ listen to music / talk with friends/family / other (specify)
4. Did you drink water while waiting? How much \_\_ mL
Trial sites (1)
Facility
City
Region
Status
BC Cancer Vancouver
Vancouver
British Columbia
Recruiting
More British Columbia Cancer Agency trials in Canada
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.